Pfizer's another big wave! Will GSK be acquired?

Source: Biovalley, August 16, 2015 When it comes to Pfizer, it's hard not to think of its blockbuster AstraZeneca acquisition last year Although the $119bn skyrocketing acquisition case was ultimately stillborn due to various pressures, Pfizer's rich and willful figure is believed to have been deeply in the eyes of all In fact, several months later, Pfizer never intended to shut down in the merger and acquisition market There have been reports that Pfizer may turn to GlaxoSmithKline, another British biomedical giant However, this news has not been unanimously agreed by all analysts One side agreed that Pfizer would benefit enough from the acquisition Not to mention that Britain's tax rate is far lower than that of the United States, GlaxoSmithKline's vaccine department and consumer health department are the long coveted assets of Pfizer For example, if Pfizer's best-selling Peier 13 vaccine is supplemented by GlaxoSmithKline's vaccine department, its future sales will be even higher Although GSK has been mentioned in the past two years, people always associate it with bribery, and GSK has paid more than 500 million dollars for the scandal But GlaxoSmithKline has swapped assets with Novartis in the past year, and its second quarter sales rose 6% year-on-year to as much as $9.2 billion In addition, GSK currently has about 40 drugs under development, 20 of which are said to be on the market in the next five years So for Pfizer, swallowing GlaxoSmithKline seems to be a lot of good But these don't seem to convince all analysts and investors Andrew Baum of Bloomberg confirmed that things are not as good as they think Because the first thing Pfizer has to face is the British government, he believes that if Pfizer wants to launch the plan, it is likely to face greater resistance from the British government On the other hand, some investors also think the plan is impractical and imply that Pfizer may seek smaller acquisition targets GSK may not be relieved, however, because Novartis, Roche and Johnson & Johnson are all salivating over some of its assets.